< Back to previous page
Researcher
Christophe Dooms
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 2009 → Today
Projects
1 - 4 of 4
- Whole transcriptome sequencing for lung adenocarcinoma diagnosisFrom1 Feb 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancerFrom1 Jan 2017 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Obstructive lung diseases: structural heterogeneity and innate immune tasks for sustained disease modification.From1 Oct 2015 → 30 Sep 2019Funding: BOF - Concerted Research Project from 1994
- Surgical Mediastinal Staging and Minimally Invasive Resection in the Treatment of Non-Small Cell Lung Cancer.From1 Sep 2014 → 23 Jan 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 167
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.(2024)
Authors: Christophe Dooms
Pages: 118 - 131 - Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary(2024)
Authors: Christophe Dooms
Pages: 113 - 120 - Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431(2023)
Authors: Christophe Dooms
Pages: S1654 - S1655 - Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer(2023)
Authors: Christophe Dooms
Pages: 491 - 503 - Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100(2023)
Authors: Christophe Dooms
Pages: 3311 - + - Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial(2023)
Authors: Christophe Dooms
Pages: 733 - 746 - Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.(2023)
Authors: Maarten Lambrecht, Christophe Dooms, Kristiaan Nackaerts, Johan Vansteenkiste, Els Wauters
Pages: 100727 - Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study(2022)
Authors: Christophe Dooms
Pages: S1419 - S1420 - Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report(2022)
Authors: Christophe Dooms, Els Wauters, Kristiaan Nackaerts
- Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis(2022)
Authors: Pierre Van Mol, Sam Vanmassenhove, Christophe Dooms, Dries Testelmans, Kristiaan Nackaerts, Johan Vansteenkiste, Robin Vos, Stephanie Humblet-Baron, Diether Lambrechts, Els Wauters